retatrutide phase 2 weight loss percentage just delivered the first top-line 3 results for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 Effects of once-weekly subcutaneous retatrutide

Projected global sales by 2030 for GLP-1 could increase by 2.6x

Enjoy fewer interruptions and one less thing to think about on your wellness journey.

Together, these presentations reflect continued progress across the elecoglipron clinical program and its potential as a once-daily oral GLP-1 receptor agonist for people living with obesity, overweight, or type 2 diabetes

Eli Lilly and Company Reports Phase 3 TRIUMPH-1 Trial Shows Up to 30.3% Weight Loss with Retatrutide in Obesity

Experts explain why you may experience fatigue

More than 80 obesity drugs are currently in the pipeline, with a strong emphasis on GLP-1 receptor agonists.